BCAL Diagnostics Limited (ASX:BDX)
0.0940
+0.0010 (1.08%)
Oct 7, 2026, 2:10 PM AEST
BCAL Diagnostics Revenue
In the fiscal year ending June 30, 2026, BCAL Diagnostics had annual revenue of 2.35M AUD, down -11.25%. BCAL Diagnostics had revenue of 1.08M in the half year ending June 30, 2026, a decrease of -8.89%. That makes BCAL Diagnostics the world's #42,734 largest public company by revenue and #894 in Australia.
Revenue
2.35M
Revenue Growth
-11.25%
P/S Ratio
14.73
Revenue / Employee
n/a
Employees
n/a
Market Cap
34.66M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 2.35M | -298.11K | -11.25% |
| Jun 30, 2025 | 2.65M | -396.37K | -13.01% |
| Jun 30, 2024 | 3.05M | 256.17K | 9.18% |
| Jun 30, 2023 | 2.79M | 2.07M | 288.29% |
| Jun 30, 2022 | 718.67K | 443.42K | 161.09% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Healius | 1.37B |
| Australian Clinical Labs | 736.15M |
| Monash IVF Group | 269.46M |
| ImExHS | 31.27M |
| Genetic Signatures | 19.33M |
| Cryosite | 16.70M |
| Microba Life Sciences | 14.76M |
| INOVIQ | 2.21M |